泌尿器科領域における新合成鎮痙剤SA-504の使用経験

Abstract

1. A new synthetic antispasmodic agent, SA-504, was given intramuscularly or intravenously to 53 patients in total consisting of 11 cases of Group I (pain in upper urinary tract), 12 of Group II (irritable bladder symptoms caused by lower urinary tract operation) and 30 of Group III (irritable bladder symptoms after treatment by endoscopy etc.), and its clinical effects were evaluated. 2. In Group 1, the result was excellent in 7 cases (63.6%), good in 2 cases (18.2%) and poor in 2 cases (18.2%), and the rate of effectiveness was 81.896; in Group II, it was excellent in 7 cases (58.3%), good in 4 cases (33.3%) and poor in one case (8.3%), and the effective rate was 91.6%; in Group III, excellent in 22 cases (73.3%), good in 7 cases (23.3%) and poor in one case (3.3%), and the effective rate was so high as 96.6%. The overall effective rate was 92.5%. 3. No noticeable side effects were observed except mild dryness of mouth encountered in only 3 cases.